SPY
—
QQQ
—
BTC/USD
—
DIA
—
GLD
—
TLT
—
US
Sign in
Register
My Account
Benzinga
Markets & News
Markets
Stocks & Sectors
Stocks
Ratings & Research
Ratings
Trading
Trading
Screeners & Lists
Screeners
Learn
Learn
Premium
Premium Services
Markets & News
Breaking headlines, the trading day, and the calendars that move it.
Stocks & Sectors
Research any ticker, then drill into sectors, ratings, and options.
Ratings & Research
Wall Street calls, insider moves, and Benzinga's own stock rankings.
Trading
Options flow, trade calculators, and ideas for active traders.
Screeners & Lists
Filter the market your way, or start from a curated list.
Learn
Pick a broker, grow your savings, and protect what you've built.
Premium Services
Edge
Ratings, signals & screens
Pro
Real-time news & data terminal
Research
Trade alerts & newsletters
APIs
Market data licensing
All sections
Insmed Inc
INSM
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$96.27
-2.94
-2.96%
Last update: Oct 16, 7:23 PM
$96.27
-2.94
-2.96%
Get Report
Overview
News
Earnings Forecast
Events
Price Targets
Financials
Sentiment
Ownership
Compare
Options
Stock Report
Privacy Manager
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga
Edge
Benzinga
Research
Benzinga
Pro
Logout
Earnings:
Q3 2026 Earnings in 11 days from now on Thu Oct 29th, before the market open
Insmed Financials
Insmed (INSM) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed
Insmed shares slip after CFO Sara Bonstein steps down, reaffirms 2026 financial targets.
Vandana Singh
PRO
Insmed Reaffirms FY26 Revenue Guidance Of $1.25B-$1.40B For BRINSUPRI And $450M- $470M For ARIKAYCE
Reaffirms Full-Year 2026 GuidanceAs Insmed continues to build on its operational excellence and momentum, the Company reaffirms its full-year 2026 financial guidance of revenue in the range of $1.25 billion to $1.40
Benzinga Newsdesk
PRO
Insmed Q2 EPS $(0.06) Beats $(0.73) Estimate, Sales $425.486M Beat $392.836M Estimate
Insmed (NASDAQ:INSM) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.73) by 91.78 percent. This is a 96.47 percent increase over losses of $(1.70) per share from the same
Benzinga Newsdesk
PRO
Insmed Raises FY2026 Sales Guidance from $1.450B-$1.470B to $1.700B-$1.870B vs $1.705B Est
Insmed (NASDAQ:INSM) raises FY2026 sales outlook from $1.450 billion-$1.470 billion to $1.700 billion-$1.870 billion vs $1.705 billion estimate.
Benzinga Newsdesk
Nasdaq 100 Climbs Records, Oil Extends Drop As Iran Weighs Hormuz Deal: Stock Market Today
U.S. stocks drifted near records Thursday as oil slipped on Iran-Hormuz peace hopes. Coinbase, Airbnb and CoreWeave on deck after the close.
Piero Cingari
PRO
Insmed Affirms FY2026 Sales Guidance of $1.450B-$1.470B vs $1.699B Est
Insmed (NASDAQ:INSM) affirms FY2026 sales outlook from $1.450 billion-$1.470 billion to $1.450 billion-$1.470 billion vs $1.699 billion estimate.
Benzinga Newsdesk
